Biomolecules and Biomedicine · 2022 · 14 citations · 22 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryDrug-likeness AssessmentPharmacodynamics Of Anticancer Drugs3D Cell Culture Models3D Cell Culture Systems3D Tumor ModelsHalf-maximal Inhibitory ConcentrationSpheroid CultureSpheroid Culture ModelsSpheroid ModelsSpheroid Potency Assays
Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC50) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids' susceptibility to treatment was more complicated; the fitness of IC50 curves of 2D and 3D tumor cell preclinical models differs significantly. IC50 curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically.
22
Clinical development success rates for investigational drugs
Michael Hay, David W. Thomas, John L. Craighead et al. · Nature Biotechnology · 2014 · 2.5K citations
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Dong Gao, Ian Vela, Andrea Sboner et al. · Cell · 2014 · 1.6K citations · Full text
Medicine, Cell Biology, Oncology +10
Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer
Yoshinori Imamura, Toru Mukohara, Yohei Shimono et al. · Oncology Reports · 2015 · 858 citations · Full text
Medicine, Cancer Biology, Oncology +15
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Marc Hafner, Mario Niepel, Mirra Chung et al. · Nature Methods · 2016 · 741 citations · Full text
Medicine, Oncology, Pharmacology +11
Dong Lin, Alexander W. Wyatt, Hui Xue et al. · Cancer Research · 2013 · 365 citations